510 related articles for article (PubMed ID: 27096164)
1. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
Liu P; Jia J; Zhao Y; Wang KZ
Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
[TBL] [Abstract][Full Text] [Related]
3. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
Alessio E; Messori L
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis ES; Emadi A
Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
[TBL] [Abstract][Full Text] [Related]
5. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
6. Development of Arene Ruthenium Antitumor Complexes.
Su W; Tang Z; Li P
Mini Rev Med Chem; 2016; 16(10):787-95. PubMed ID: 27161008
[TBL] [Abstract][Full Text] [Related]
7. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
8. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
Silva Dde O
Anticancer Agents Med Chem; 2010 May; 10(4):312-23. PubMed ID: 20380636
[TBL] [Abstract][Full Text] [Related]
9. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
Notaro A; Gasser G
Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
Thota S
Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
[No Abstract] [Full Text] [Related]
11. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
13. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
Biancalana L; Pampaloni G; Marchetti F
Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
[TBL] [Abstract][Full Text] [Related]
14. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
Groessl M; Zava O; Dyson PJ
Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
[TBL] [Abstract][Full Text] [Related]
15. First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.
Valente A; Garcia MH; Marques F; Miao Y; Rousseau C; Zinck P
J Inorg Biochem; 2013 Oct; 127():79-81. PubMed ID: 23896008
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
Abid M; Shamsi F; Azam A
Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
[TBL] [Abstract][Full Text] [Related]
17. New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.
Bratsos I; Simonin C; Zangrando E; Gianferrara T; Bergamo A; Alessio E
Dalton Trans; 2011 Oct; 40(37):9533-43. PubMed ID: 21853191
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
[TBL] [Abstract][Full Text] [Related]
19. Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.
Gano L; Pinheiro T; Matos AP; Tortosa F; Jorge TF; Gonçalves MS; Martins M; Morais TS; Valente A; Tomaz AI; Garcia MH; Marques F
Anticancer Agents Med Chem; 2019; 19(10):1262-1275. PubMed ID: 30887931
[TBL] [Abstract][Full Text] [Related]
20. Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer.
Franco Machado J; Machuqueiro M; Marques F; Robalo MP; Piedade MFM; Garcia MH; Correia JDG; Morais TS
Dalton Trans; 2020 May; 49(18):5974-5987. PubMed ID: 32314752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
